Abstracts Archive - Page 1246 of 2425 - ACR Meeting Abstracts

Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 608 • 2017 ACR/ARHP Annual Meeting
Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study
Philip J Mease¹, Iain B. McInnes², Vibeke Strand³, O FitzGerald⁴, H Ahmad⁵, A Johnsen⁵, J Ye⁵ and S Banerjee⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Stanford University, Palo Alto, CA, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, significantly increased ACR20 response and had an overall beneficial effect on musculoskeletal symptoms in patients with active psoriatic…
Abstract Number: 609 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Iain B. McInnes¹, Gianfranco Ferraccioli², MA D'Agostino³, M Le Bars⁴, S Banerjee⁵, H Ahmad⁵, Y Elbez⁶, J Ye⁵ and Philip J Mease⁷, ¹University of Glasgow, Glasgow, Great Britain, ²Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Hôpital Ambroise Paré, Boulogne-Billancourt, France, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Excelya, Boulogne-Billancourt, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to…
Abstract Number: 610 • 2017 ACR/ARHP Annual Meeting
Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study
Georg Schett¹, T Lehman², HA Ahmad², A Johnsen², S Banerjee² and Philip J Mease³, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease in which treatment selection and patient stratification based on clinical domains have recently been proposed.1 The efficacy…
Abstract Number: 611 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Early Adalimumab Therapy in Psoriatic Arthritis Patients from Reuma.Pt
Helena Santos¹, Mónica Eusébio², Joana Borges³, Diana Gonçalves⁴, Pedro Ávila-Ribeiro⁵, Daniela Santos Faria⁶, Carina Lopes⁷, João Rovisco⁸, Ana Águeda⁹, Patrícia Nero¹⁰, Paula Valente¹¹, Ana Rita Cravo¹² and Maria José Santos¹³, ¹Instituto Português de Reumatologia, Lisbon, Portugal, ²Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ³Instituto Português de Reumatologia, Lisboa, Portugal, ⁴Centro Hospitalar de São João, Coimbra, Portugal, ⁵Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁶ULSAM, Ponte de Lima, Portugal, ⁷Hospital de Egas Moniz-CHLO, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Lisbon, Portugal, ⁹Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁰Hospital CUF Descobertas, Lisbon, Portugal, ¹¹Centro Hospitalar Entre o Douro e Vouga, Lisbon, Portugal, ¹²Medical, AbbVie, Lisbon, Portugal, ¹³Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: There is a lack of evidence on the effect of biologics in early treatment of psoriatic arthritis (PsA) patients (Pts). Benefit of concomitant use…
Abstract Number: 612 • 2017 ACR/ARHP Annual Meeting
Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period
Regan Arendse¹, Anna Jaroszynska², Derek Haaland³, Pauline Boulos⁴, Isabelle Fortin⁵, Raheem Kherani⁶, Ariel Masetto⁷, Jonathan Chan⁸, Eliofotisti Psaradellis⁹, Melissa Stutz⁹, Brendan Osborne¹⁰, Francois Nantel¹⁰ and Allen J Lehman¹¹, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶University of British Columbia, Richmond, BC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Ustekinumab (UST) is a fully human immunoglobin monoclonal antibody against interleukin-12 (IL-12) and interleukin-23 (IL-23) that has been proven safe and efficacious for the…
Abstract Number: 613 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
Hervé Bachelez¹, Christopher EM Griffiths², Kim Papp³, Stephen Hall⁴, Joseph F Merola⁵, Steven R Feldman⁶, Majed Khraishi⁷, Anna Tallman⁸, Huaming Tan⁹ and Ming-Ann Hsu⁹, ¹Sorbonne Paris Cité Université Paris Diderot, AP-HP Hôpital St. Louis, Paris, France, ²Dermatology Centre, University of Manchester, Manchester, United Kingdom, ³Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁴Emeritus Research, Melbourne, Australia, ⁵Harvard Medical School, Boston, MA, ⁶School of Medicine, Wake Forest University, Winston-Salem, NC, ⁷Memorial University of Newfoundland, St. John's, NF, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Up to 42% of patients (pts) with psoriasis…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 615 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials
Alan J. Kivitz¹, Oliver FitzGerald², Peter Nash³, Shirley Pang⁴, Valderilio F Azevedo⁵, Elizabeth Kudlacz⁶, Cunshan Wang⁶, Daniela Graham⁶ and Liza Takiya⁷, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴St. Jude Medical Center, Fullerton, CA, ⁵Universidade Federal do Paraná, Curitiba, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3…
Abstract Number: 616 • 2017 ACR/ARHP Annual Meeting
Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
Gerd R. Burmester¹, Oliver FitzGerald², Kevin Winthrop³, Valderilio F Azevedo⁴, William F C Rigby⁵, Keith S Kanik⁶, Cunshan Wang⁶, Pinaki Biswas⁷, Thomas Jones⁸, Sujatha Menon⁶, Niki Palmetto⁷ and Ricardo Rojo⁶, ¹Charité - University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Oregon Health & Science University, Portland, OR, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). We describe the safety profile of tofacitinib from integrated Phase (P)3…
Abstract Number: 617 • 2017 ACR/ARHP Annual Meeting
Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-World Data
Jeffrey R. Curtis¹, Huifeng Yun¹, Oliver FitzGerald², Kevin Winthrop³, Valderilio F Azevedo⁴, Gerd R. Burmester⁵, William F C Rigby⁶, Keith S Kanik⁷, Ricardo Rojo⁷, Sujatha Menon⁷, Cunshan Wang⁷, Pinaki Biswas⁸, Thijs Hendrikx⁹ and Niki Palmetto⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Oregon Health & Science University, Portland, OR, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Two Phase 3 studies have been completed (NCT01877668;…
Abstract Number: 618 • 2017 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Paul Emery¹, Iain B. McInnes², Philip J Mease³, Michael Schiff⁴, Luminita Pricop⁵, Steven Shen⁵, Zailong Wang⁵ and Corine Gaillez⁶, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Colorado, Denver, CO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…
Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Peter Nash¹, Laura C Coates², Roy Fleischmann³, Kim Papp⁴, Juan J. Gomez-Reino⁵, Keith S Kanik⁶, Cunshan Wang⁶, Joseph Wu⁶, Thijs Hendrikx⁷ and William C Ports⁶, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…
Abstract Number: 620 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Peter Nash¹, Laura C Coates², Alan J. Kivitz³, Philip J Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data up to January 2017 (database not locked) report the…
Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Josef S. Smolen¹, Philip J Mease², Christopher T. Ritchlin³, Tore K Kvien⁴, Luminita Pricop⁵, Todd Fox⁶, Lawrence Rasouliyan⁷, Steffen Jugl⁶ and Corine Gaillez⁶, ¹Medical University of Vienna, Vienna, Austria, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].